I agree. The common theme and longtime hindran
Post# of 148175
The common theme and longtime hindrance is cash (keeps CYDY on OTC, limits trial progress, PR reach, etc.). I'm sure they could do a better job turning over rocks and creating buzz, but efforts like that are likely come at a premium. I wouldn't think any PR firm will has an "only turning rocks and creating buzz" package......it is likely structured as a base + option 1, option 2, etc. with an associated dollar amount. We will get there, but IMO right now until cash allows I believe they will continue to advance the science that will create the "world series" buzz on its own as you said. FWIW, I agree with this course of action......funding priorities after science to me are paying liabilities, paying off convertible notes and then PR option packages.